Tata's wanted to reenter pharma and their first major investment was in Advinus Therapeutics Pvt. ltd, a start-up with focus on drug discovery. The brain behind the venture is Rashmi Barbhaiya. Developing novel therapies for neglected diseases such as Leshmaniasis, dengue fever, tuberculosis, leprosy and malaria is one of its priority area. As big drug companies shut down some research facilities in the U.S. and other rich countries, labs in India and China are increasingly picking up the slack. Eli Lilly & Co., Wyeth and GlaxoSmithKline PLC all have outsourced chemistry work to Indian firms.